Vidya Kesavan
Staff Affiliate - OtherAbout
Copy Link
Titles
Staff Affiliate - Other
Research
Copy Link
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
IRB ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
IRB ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
IRB ID2000028827RoleSub InvestigatorPrimary Completion Date12/15/2024Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
IRB ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting ParticipantsA Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
IRB ID2000030007RoleSub InvestigatorPrimary Completion Date08/01/2026Recruiting Participants